Blood-based Biomarker For Sports Medicine Market To Reach $1.16 Billion By 2030

Blood-Based Biomarker For Sports Medicine Market Growth & Trends

The global blood-based biomarker for sports medicine market size is anticipated to reach USD 1.16 billion by 2030 and is anticipated to expand at a CAGR of 6.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing focus on personalized health, advancements in biomarker technology, and growing demand for accurate performance & recovery assessments. Moreover, rising awareness of sports-related injuries and the need for precise diagnostics also contribute to market growth & innovation.

The growing emphasis on R&D and rising investments in sports medicine are significantly driving the market expansion. As the sports medicine field evolves, there is an increasing focus on understanding the complex physiological responses of athletes through advanced biomarkers. Investment in sports medicine research is promoting significant advancements in blood-based biomarker technologies. Companies and research institutions are investing heavily in developing high-throughput screening methods and advanced data analytics to improve biomarker detection and interpretation. The growing investment from public and private organizations further propels the demand for advanced biomarkers in sports medicine.

Moreover, the predictive potential of biomarkers is also being investigated to predict injury risks before they occur. According to research published in Frontiers in Physiology, advanced research focuses on oxidative stress and inflammation biomarkers to predict injury susceptibility. This predictive capability is valuable for preventive strategies, helping athletes avoid injuries through proactive measures. As a result, the market for blood-based biomarkers in sports medicine is experiencing significant growth.

 Request a free sample copy or view report summary: Blood-based Biomarker For Sports Medicine Market Report

Blood-Based Biomarker For Sports Medicine Market Report Highlights

• The creatine kinase (CK) segment accounted for the largest revenue share at 18.0% in 2023. The demand for CK testing is driven by the increasing focus on injury prevention and management and increasing awareness among athletes & sports teams about the importance of preventing overtraining and optimizing recovery

• Some of the key players operating in the blood-based biomarkers for sports medicine market are Abbott, BIOMÉRIEUX, F. Hoffmann-La Roche Ltd., ARUP Laboratories, Siemens Healthineers AG, and RayBiotech, Inc. Furthermore, the market is witnessing the emergence of new and innovative products from new players, as well as strategic partnerships among key market players to develop new offerings

• In March 2023, Abbott obtained clearance from the U.S. FDA for the first commercially available laboratory blood test for TBI, allowing it to be widely accessible in U.S. hospitals. The test detects two biomarkers in the blood, which, when present at elevated levels, are strongly associated with brain injury

Blood-Based Biomarker For Sports Medicine Market Segmentation

Grand View Research has segmented the global blood-based biomarker for sports medicine based on type and region:

Blood-based Biomarker For Sports Medicine Type Outlook (Revenue, USD Million, 2018 - 2030)

• CK

• Myoglobin

• Lactate

• WBC

• Urea

• CRP

• Lipid And Protein Hydroperoxides

• IL-6

• Others

Blood-based Biomarker For Sports Medicine Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • New Zealand

  • Taiwan

  • Hong Kong

  • Singapore

  • Thailand

  • Vietnam

• Latin America

  • Brazil

  • Argentina

  • Chile

• Middle East and Africa(MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Egypt

  • Qatar

List of Key Players in the Blood-based Biomarker For Sports Medicine Market

• Abbott

• BIOMÉRIEUX

• F. Hoffmann-La Roche Ltd.

• ARUP Laboratories

• Siemens Healthineers AG

• RayBiotech, Inc

• Thermo Fisher Scientific, Inc.

• Bio-Rad Laboratories, Inc

• Beckman Coulter, Inc.

• Randox Laboratories Ltd.